ASP Isotopes Acquires Radiopharmacy & Secures Silicon-28 Supply Deal

By Hao Liu • Tuesday, October 14 10:29 • Permanent Link

ASP Isotopes Inc. (NASDAQ: ASPI) has provided a business development update, including a supply agreement for enriched silicon-28 and a strategic acquisition of a radiopharmacy in the United States. The company has entered into a supply contract with a U.S.-based customer for enriched silicon-28, with deliveries expected during Q1 2026. This represents the company's largest silicon-28 contract to date.

The acquisition of an independent radiopharmacy in Florida, United States, aligns with the company's strategy to expand its nuclear medicine business and represents its first expansion outside South Africa. This acquisition is expected to be accretive to 2026 revenues, EBITDA, and EPS.

The supply contract for enriched silicon-28 underscores the company's electronic gases strategy gaining traction across multiple end markets. Enriched silicon-28 is a key material in the development of solid-state quantum computing and advanced semiconductor architectures. The ability to supply this material at commercial scale marks an important step toward establishing a robust and diversified supply chain for the next generation of computing technologies.

The company's acquisition of the radiopharmacy in Florida is expected to complement and expand the operations of its South African radiopharmaceutical operations company, Pet Labs Pharmaceuticals (Pty) Ltd. This small acquisition is expected to be accretive to revenues, EBITDA, and EPS during 2026.

The company has a strategy to further expand Pet Labs' business and activities in the United States and other jurisdictions to meet the increasing demand for radiodiagnostics and radiotherapeutics. Pet Labs aims to build a radiopharmacy network that is vertically integrated with the capabilities to produce stable isotopes used for the production of radioisotopes.

Dr. Gerdus Kemp, CEO of Pet Labs, commented that the acquisition marks the first important step in the planned expansion of Pet Labs outside South Africa. The company expects to grow Pet Labs with both brownfield and greenfield expansions, with the goal to ultimately turn Pet Labs into a global leader in the production of radioisotopes to treat various forms of oncology.

The market has reacted to these announcements by moving the company's shares 31.49% to a price of $13.32. For the full picture, make sure to review ASP Isotopes's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.